Latest Current Report
Filed: 2026-04-16
Key Insights
- Acurx Pharmaceuticals has raised approximately $2.5 million in a registered direct offering, which it intends to use for working capital and general corporate purposes.
- The company has issued pre-funded warrants and Series H warrants to investors, providing additional financing and potential future equity.
- Acurx has agreed to certain restrictions on future equity issuances and entered into an engagement letter with H.C. Wainwright & Co. to serve as the exclusive placement agent for the offering.